ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0160

Supplement Use in a Diverse Cohort of Individuals with SLE

Russell Ellyson1, Jinoos Yazdany2, S. Sam Lim3, Brad Pearce3 and Laura Plantinga4, 1Alameda Health System, Highland Hospital, Oakland, CA, 2UCSF, San Francisco, CA, 3Emory University, Atlanta, GA, 4University of California, San Francisco, San Francisco, CA

Meeting: ACR Convergence 2024

Keywords: Epidemiology, Minority Health, Systemic lupus erythematosus (SLE), Therapy, complementary

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Epidemiology & Public Health Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Supplement use among individuals with SLE is not well-characterized, despite potential effects of some supplements on SLE activity or on treatments for SLE or its associated comorbidities. Further, some supplements may interact with important lab values [e.g., vitamin B7 (biotin) interferes with assays for troponin, hormones (e.g., thyroid-stimulating hormone), and vitamin D]. We estimated the prevalence of overall and individual supplement use in a primarily Black U.S. cohort of individuals with SLE.

Methods: Participants were recruited from an ongoing population-based SLE cohort [Georgians Organized Against Lupus (GOAL)] and asked to report their current supplements during a single study visit (10/2019-5/2022). Descriptive statistics were calculated overall and by age, sex, and race, with statistical comparisons by chi-square test. The most common supplements were defined as >5% of participants reporting use. Supplements with potential effects on SLE or treatments or potential interference with lab tests were identified via NIH and FDA sources.

Results: Overall, 87.4% of participants (N=451; mean age, 46.2 years; 91.8% female and 82.5% Black) reported taking at least one supplement. The median number of supplements reported was 2 (25th-75th percentile, 1-3; range, 0-12), and 66.7% of participants were taking two or more supplements. Prevalence estimates did not differ by age, sex, or race (Figure 1). The most commonly reported supplements were vitamin D (64.1%), multivitamins (45.2%), and vitamin B12 (10.6%), as well as other B vitamins (vitamin B1 and biotin), vitamin C, iron, magnesium, melatonin, and curcumin (turmeric) (Figure 2). While less common, some participants were using supplements that have theoretical immune-activating effects, such as ashwagandha (0.4%) and echinacea (0.2%), or have unknown health implications, such as colloidal silver (0.2%).

Conclusion: Supplement use in our cohort was common, with most participants reporting taking at least one supplement and about two-thirds reporting taking two or more. Some supplements (e.g., vitamin D and multivitamin) may be recommended or prescribed by a physician and beneficial in the setting of SLE. However, other reported supplements may pose risks for immune activation (e.g., echinacea) or interfere with lab tests (e.g., biotin). Given the variety of supplements available, the lack of consistent regulation of ingredients, and wide distribution of misinformation, it is very important for physicians to assess supplement use in their patients, encourage patients to use trusted information sources, and be aware of the potential benefits and risks associated with commonly used supplements.

Supporting image 1

Figure 1. Prevalence of self-reported supplement use among individuals with SLE. P>0.05 for all comparisons.

Supporting image 2

Figure 2. Most common (>5% reporting) supplements reported by individuals with SLE.


Disclosures: R. Ellyson: None; J. Yazdany: AstraZeneca, 2, Aurinia, 5, Bristol-Myers Squibb(BMS), 2, UCB, 2; S. Lim: Accordant, 2, AstraZeneca, 2, Biogen, 5, BMS, 5, Gilead, 5, GSK, 2, Novartis, 5, UCB, 5; B. Pearce: None; L. Plantinga: None.

To cite this abstract in AMA style:

Ellyson R, Yazdany J, Lim S, Pearce B, Plantinga L. Supplement Use in a Diverse Cohort of Individuals with SLE [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/supplement-use-in-a-diverse-cohort-of-individuals-with-sle/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/supplement-use-in-a-diverse-cohort-of-individuals-with-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology